Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-15 and Docetaxel in Metastatic or Recurrent Breast Carcinoma
NCT00028483Phase 2Terminated
- Sponsor
- Seagen Inc.
- Start
- Oct 2000
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SGN-15 in breast carcinoma, sponsored by Seagen Inc. Primary endpoints: Toxicity and safety profile and Clinical Response Rate. Started Oct 2000; status: terminated.
02
Drugs
SGN-15
03
Conditions
breast carcinoma
Beyond the preview
Go deeper on NCT00028483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00028483.